Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D85NEG
|
|||
| Drug Name |
BAY 2253651
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obstructive sleep apnea [ICD-11: 7A41; ICD-9: 327.23, 780.57] | Phase 2 | [1] | |
| Company |
Bayer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TWIK-related acid-sensitive potassium channel 1 (TASK1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Aldosterone synthesis and secretion | |||
| Cortisol synthesis and secretion | ||||
| Cushing syndrome | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03603678) Obstructive Sleep Apnea (OSA) Treated With a Potassium Channel Inhibitor (SANDMAN). U.S. National Institutes of Health. | |||
| REF 2 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.